StockNews.com Begins Coverage on Oncternal Therapeutics (NASDAQ:ONCT)

StockNews.com started coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a research note published on Tuesday. The firm issued a hold rating on the stock.

A number of other research firms have also recently issued reports on ONCT. Northland Capmk cut shares of Oncternal Therapeutics from a strong-buy rating to a hold rating in a research note on Thursday, September 12th. Northland Securities restated a market perform rating and set a $2.00 price objective on shares of Oncternal Therapeutics in a research report on Thursday, September 12th. HC Wainwright decreased their target price on Oncternal Therapeutics from $19.00 to $18.00 and set a buy rating on the stock in a research report on Monday, August 12th. Finally, Brookline Capital Management reissued a hold rating on shares of Oncternal Therapeutics in a report on Thursday, September 12th. Four equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of Hold and a consensus price target of $20.00.

Oncternal Therapeutics Stock Performance

Oncternal Therapeutics stock opened at $1.45 on Tuesday. The stock has a 50-day simple moving average of $4.43 and a 200 day simple moving average of $7.01. The stock has a market capitalization of $4.29 million, a P/E ratio of -0.12 and a beta of 1.39. Oncternal Therapeutics has a 52 week low of $1.32 and a 52 week high of $13.14.

Oncternal Therapeutics (NASDAQ:ONCT) last issued its earnings results on Thursday, August 8th. The company reported ($2.89) EPS for the quarter, topping the consensus estimate of ($3.03) by $0.14. Oncternal Therapeutics had a negative return on equity of 136.10% and a negative net margin of 1,948.70%. The company had revenue of $0.80 million during the quarter, compared to the consensus estimate of $0.24 million. During the same period in the previous year, the company posted ($3.00) EPS. Research analysts forecast that Oncternal Therapeutics will post -11.43 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Oncternal Therapeutics stock. Quantum Private Wealth LLC purchased a new position in shares of Oncternal Therapeutics, Inc. (NASDAQ:ONCT) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 27,806 shares of the company’s stock, valued at approximately $250,000. Quantum Private Wealth LLC owned approximately 0.94% of Oncternal Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 16.05% of the company’s stock.

About Oncternal Therapeutics

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.